v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Cash flows from operating activities:    
Net income (loss) $ (19,424,654) $ 30,656,050
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on related party investment - QCLS (2,089,000) (21,395,734)
Issuance costs – Series C preferred stock and warrants 1,234,553 0
Loss on issuance of Series C preferred stock 215,000 0
Gain on re-fair value of warrants (106,000) 0
Non-cash interest income (162,500) (300,000)
Non-cash warrant liability 0 469,000
Intangible asset impairment 1,549,427 0
Stock issued for compensation - RSUs 892,500 0
Stock-based compensation - options 236,056 478,637
Unrealized (gain) loss on marketable equity securities 412,306 (66,316)
Change in fair value of warrant liability 4,746,135 (10,446,000)
Change in fair value of derivative liability (1,117,000) (2,184,000)
Change in fair value of convertible note receivable - Femasys (1,304,000) (941,000)
Change in fair value of warrant assets - Femasys 2,581,000 2,091,000
Change in fair value of investment - QCLS 7,732,000 (5,063,950)
Change in fair value of warrants - QCLS 1,379,000 2,367,684
Change in assets and liabilities:    
(Increase) decrease in prepaid expenses and other current assets (251,386) 36,041
Increase (decrease) in accounts payable (128,102) 9,835
Increase (decrease) in accrued expenses (1,548,249) 1,310,457
Net cash used in operating activities (5,152,914) (2,978,296)
Cash flows from investing activities:    
Investment in preferred stock and warrants - QCLS (3,000,000) (7,000,000)
Proceeds from investment – note receivable 5,000,000 0
Net cash provided by (used in) investing activities 2,000,000 (7,000,000)
Cash flows from financing activities:    
Repurchase of common stock, net (401,625) (2,542,276)
Net proceeds from issuance of Series C preferred stock 6,182,447 0
Redemption of preferred stock 0 (22,486,875)
Payment of Series C convertible preferred stock dividends (246,005) 0
Net proceeds from warrant exercise 1,046,760 0
Net cash provided by (used in) financing activities 6,581,577 (25,029,151)
Effect of currency rate exchange on cash and cash equivalents 3,073 (358)
Net increase (decrease) in cash and cash equivalents 3,431,736 (35,007,805)
Cash and cash equivalents at beginning of the year 15,172,163 50,179,968
Cash and cash equivalents at end of the year 18,603,899 15,172,163
Supplemental disclosure of cash flows information:    
Cash paid during the year for income taxes 0 0
Supplemental schedule of non-cash investing and financing activities:    
Accrual of Series C Convertible Preferred Stock dividends 278,496 0
Accretion of discounts to redemption value of Series C Preferred Stock 3,503,222 0
Initial fair value of investment in QCLS Series H preferred shares 3,483,000 0
Initial fair value of investment in QCLS Series H warrants 1,606,000 0
Non-cash derivative liability at initial fair value 1,995,000 0
Non-cash warrant liability at initial fair value 5,220,000 0
Non-cash conversion of Series C convertible stock 2,234,330 0
Change in fair value associated warrant exercises 599,135 0
Fair value of contingently redeemable placement agent warrants 417,000 0
Series B Convertible Preferred Stock dividends 0 1,129,759
Accretion of discounts to redemption value of Series B Convertible Preferred Stock 0 3,193,404
Excise tax accrued on repurchase of common stock $ 0 $ 25,424